NCT05643872View on ClinicalTrials.gov

A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

PHASE3RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

October 31, 2023

Study Completion Date

November 30, 2023

Conditions
Pachyonychia Congenita
Interventions
DRUG

PTX-022

QTORIN rapamycin 3.9% anhydrous gel

Trial Locations (1)

55112

RECRUITING

Minnesota Clinical Study Center, New Brighton

Sponsors
All Listed Sponsors
lead

Palvella Therapeutics, Inc.

INDUSTRY

NCT05643872 - A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita | Biotech Hunter | Biotech Hunter